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Hyperproliferative keratinocytes induced by trauma, hyperkeratosis and/or inflammation 22 
display molecular signatures similar to those of palmoplantar epidermis. Inherited gain-of-23 
function mutations in RHBDF2 (encoding iRHOM2) are associated with a hyperproliferative 24 
palmoplantar keratoderma and squamous oesophageal cancer syndrome (termed TOC). In 25 
contrast, genetic ablation of rhbdf2 in mice leads to a thinning of the mammalian footpad, 26 
and reduces keratinocyte hyperproliferation and migration. Here, we report that iRHOM2 is 27 
a novel target gene of p63 and that both p63 and iRHOM2 differentially regulate cellular 28 
stress-associated signalling pathways in normal and hyperproliferative keratinocytes. We 29 
demonstrate that p63-iRHOM2 regulates cell survival and response to oxidative stress via 30 
modulation of SURVIVINandCytoglobin, respectively. Furthermore, the antioxidant 31 
compound Sulforaphane downregulates p63-iRHOM2 expression, leading to reduced 32 
proliferation, inflammation, survival and ROS production. These findings elucidate a novel 33 
p63 associated pathway that identifies iRHOM2 modulation as a potential therapeutic target 34 
to treat hyperproliferative skin disease and neoplasia. 35 
Introduction 36 
 37 
Keratinocyte hyperproliferation and inflammation are common to many skin disorders, from 38 
the more prevalent conditions such as psoriasis and atopic eczema to the rarer monogenic 39 
skin diseases which include the palmoplantar keratodermas (PPKs). The PPKs are 40 
characterised by different patterns of hyperproliferative thickening of the palms and soles, 41 
which are often painful 1,2. Furthermore, PPK can also be associated with non-cutaneous 42 
conditions such as hearing loss, cardiomyopathy and oesophageal cancer 3,4. For example, 43 
inherited dominant mutations in RHBDF2, the gene encoding iRHOM2, are the genetic basis 44 
of the inherited syndrome Tylosis (Palmoplantar keratoderma, PPK) with Oesophageal 45 
Cancer (TOC, OMIM: 148500) 5. 46 
 47 
iRHOM2 is an inactive member of the seven transmembrane family of Rhomboid serine 48 
proteases 6. iRHOM2 can control activation and trafficking of ADAM17 (also known as TACE; 49 
TNFα converting enzyme) from endoplasmic reticulum to the Golgi and then to the cell 50 
surface 7-10. ADAM17 is a membrane-anchored metalloprotease with a wide range of 51 
substrates including cytokines (TNFα, IL-6), many receptors (IL-6R, TNF-R), growth factors 52 
(TGFα, AREG) and adhesion proteins 11. The autosomal dominant TOC-associated missense 53 
mutations, located in the highly conserved cytoplasmic amino-terminal domain of iRHOM2, 54 
lead to increased ADAM17 activity and the “shedding” of its associated substrates at the cell 55 
surface 9. TOC keratinocytes have constitutively high levels of, for example, TGFα, AREG, IL-56 
6R and IL-6. Thus, TOC-associated iRHOM2 mutations promote cell growth and migration in 57 
keratinocytes, exhibiting similar features to the inflammatory skin disease psoriasis, 58 
epithelial cancer cell lines and have a constitutive wound healing phenotype 5,12. 59 
 60 
We have recently described 12 an important role for iRHOM2 in the regulation of the 61 
epithelial response to physical stress by identifying Keratin 16 (K16) as a novel interacting 62 
binding partner. TOC-associated iRHOM2 alters the dynamics of K16 regulation, including 63 
the hetero-dimerisation with its type II binding partner K6. In vitro depletion of iRHOM2 in 64 
TOC keratinocytes reduced K16 expression, proliferation and inflammation signalling. In 65 
contrast to the hyperproliferative TOC palmoplantar epidermis, irhom2-/- mice have a much 66 
thinner footpad epidermis compared to control mice. This striking cutaneous phenotype is 67 
associated with loss of K16 expression. 68 
 69 
In this study we showed different signalling mechanisms between normal interfollicular and 70 
palmoplantar epidermis. The stressed palmoplantar epidermis mirrors disorders of 71 
keratinocyte hyperproliferation. To date, no studies have investigated the transcriptional 72 
regulation of iRHOM2. Here, we demonstrate that iRHOM2 is a direct molecular target of 73 
the transcription factor p63, the “master regulator” of epithelial development 13,14. 74 
Alteration of p63 expression is observed in oesophageal cancer, not only in carcinomas, but 75 
also in dysplasia 15,16. TP63 is expressed as multiple isoforms from alternative promoters 76 
with the N-terminal transactivation (TA) domain or dominant-negative (ΔN) and, in addition, 77 
these TAp63 and ΔNp63 transcripts can be alternatively spliced at the C-terminus to 78 
generate proteins designated α, β, and γ 13. The ΔNp63α isoform of p63 is expressed at high 79 
levels in the proliferative basal layer of the epidermis, suggesting the important role for this 80 
isoform in the biology of epithelial cells 13. Recent studies have described that ΔNp63 81 
overexpressing mice exhibits hyperproliferation, defects in terminal differentiation and an 82 
inflamed skin phenotype, demonstrating a key role of ΔNp63 in inflammatory skin disease 83 
17,18.  84 
 85 
We show that, in the normal keratinocytes physiological state, p63 positively regulates 86 
iRHOM2, while iRHOM2 antagonizes ΔNp63 expression. In contrast, in hyperproliferative 87 
keratinocytes, there is an auto-regulatory feedback loop occurring between ΔNp63 and 88 
iRHOM2. We show that p63-iRHOM2 mediated signalling regulates ADAM17 activity and 89 
cellular functions including inflammation, proliferation, survival and oxidative defence. 90 
Furthermore, we identify SURVIVINas a novel binding partner of iRHOM2 and as a p63 91 
target gene. In addition, we also reveal a role of iRHOM2 in the epidermal oxidative defence 92 
response via its interaction with Cytoglobin(CYGB), a reported p63 target gene. Our findings 93 
implicate a novel signalling pathway involving p63 and iRHOM2 in the control of 94 




p63 regulates iRHOM2 expression in normal keratinocytes 99 
To identify transcriptional regulators of iRHOM2, specifically if the RHBDF2 gene encoding 100 
iRHOM2 may be a direct p63 target, we analyzed the available p63 ChIP-seq dataset 101 
performed in human and mouse keratinocytes19 20 . This revealed that the human and 102 
mouse p63 binding sites are very well conserved at the intragenic region (Fig. 1a and 103 
Supplementary Fig. 1a). Furthermore, ChIP-qPCR confirmed that p63 binds to RHBDF2 gene 104 
locus (Fig. 1b). In addition, ChIP-qPCR analysis for the specific binding of p63 was performed 105 
with p21 (positive control), Thymidine kinase TK (negative control) and a no-gene region 106 
(Chr11) (Supplementary Fig.1b). These data indicate that p63 binds to the intragenic 107 
enhancer region of RHBDF2 and that iRHOM2 is a direct p63 target gene. In addition, we 108 
cloned this specific intragenic region, into the pGL3 enhancer plasmid 19, and tested 109 
whether the luciferase reporter gene activity is induced by TAp63α and ΔNp63α in HEK293 110 
cells (Human Embryonic Kidney cells). As shown in Fig. 1c, both TAp63α and ΔNp63α 111 
markedly upregulated luciferase activity. To further investigate whether p63 binding to 112 
iRHOM2 intragenic region affects iRHOM2 expression, each p63 isoform (ΔNp63α, ΔNp63β, 113 
ΔNp63γ, TAp63α, TAp63β, TAp63γ) was transiently transfected in HEK293 cells. qRT-PCR and 114 
western blot analysis showed that overexpression of the p63 isoforms modulate iRHOM2 115 
expression, in particular TAp63α and ΔNp63α significantly induce iRHOM2 expression at 116 
mRNA and protein levels (Fig. 1d and e). Additionally, depletion of p63 in keratinocytes by a 117 
small interfering RNA (siRNA) which targets all p63 isoforms 21 significantly reduced 118 
endogenous iRHOM2 protein expression (Fig. 1f) as well as at the mRNA level 119 
(Supplementary Fig. 1c). Our data suggest that ΔNp63α, the major p63 isoform expressed in 120 
epidermis, is also the major p63 isoform that regulates iRHOM2 in keratinocytes. 121 
To further investigate the expression of iRHOM2 in keratinocytes, HaCaT keratinocyte 122 
differentiation was induced in vitro by adding Ca2+ to the culture medium. iRHOM2 123 
expression was upregulated upon the induction of differentiation in a time-dependent 124 
manner (Supplementary Fig. 1d). ΔNp63, keratin 14 (K14) and involucrin expression was 125 
assessed by western blotting to confirm that the keratinocytes were undergoing 126 
differentiation. As expected, ΔNp63 and K14, highly expressed under proliferative 127 
conditions, were reduced upon the induction of differentiation while involucrin expression 128 
was upregulated. Additionally, we also validated by qRT-PCR the increase expression of 129 
RHBDF2 at mRNA levels upon Ca2+ shift (Supplementary Fig. 1e) and K14 was used as a 130 
control of the differentiation state. Moreover, iRHOM2 is expressed in the cytoplasm and 131 
plasma membrane of the basal and suprabasal layers of human epidermis (Supplementary 132 
Fig. 1f). Taken together, these results demonstrate that iRHOM2 is a transcriptional target of 133 
p63 and suggests that iRHOM2 might be implicated in the regulation of epidermal 134 
differentiation. 135 
Distinct regulation of p63 expression in keratinocytes 136 
Examination of the morphology of the stratified epithelia revealed a thicker epidermis in 137 
TOC compared with normal interfollicular skin as previously reported 9,22 (Fig. 2a). 138 
Immunohistochemistry showed increased p63 expression in the nuclei of the basal and 139 
suprabasal layers in TOC epidermis compared to control interfollicular skin (Fig. 2a). To 140 
better delineate the basal cells of the epidermis, we also performed immunofluorescence 141 
staining for Keratin 14 (K14), a marker of the basal layer (Supplementary Fig. 2a). Similarly, 142 
in the immortalised TOC keratinocytes, ΔNp63 was upregulated at the mRNA and protein 143 
levels when compared to control keratinocytes (Supplementary Fig. 2b and 2c). Microscopic 144 
examination of haematoxylin and eosin-stained skin sections showed no significant 145 
difference in the thickness of the rhbdf2-/- mice back skin compared to wild-type controls, 146 
while the rhbdf2-/- mice paw revealed a thinner epidermis compared to rhbdf2+/+ mice as 147 
published previously 12. Back skin and footpads from rhbdf2-/- mice were immunostained for 148 
p63 and analysed by confocal microscopy (Fig.2b). rhbdf2-/- mice showed increased p63 149 
expression in the back skin but had reduced expression in their footpad epidermis 150 
compared to rhbdf2+/+ littermates (Fig. 2b). K14 was also used to delineate the basal cells of 151 
the epidermis (Supplementary Fig. 2d), as a “bona fide” target of p63, interestingly, K14 152 
follows the same p63 expression pattern. In addition, we also confirmed modulation of p63 153 
expression by qRT-PCR and western blot analysis of extracts derived from paw and back skin 154 
of rhbdf2+/+ and rhbdf2-/- mice. (Fig. 2c and Supplementary Fig. 2e). To investigate this 155 
apparent cell-context regulation of p63 by iRHOM2, we next used short hairpin RNA (shRNA) 156 
knockdown of iRHOM2, which was found to increase ΔNp63 protein expression in control 157 
keratinocytes, while sh-iRHOM2 TOC keratinocytes resulted in a downregulation of ΔNp63 158 
expression (Supplementary Fig. 2f). These observations indicate that, in interfollicular skin, 159 
iRHOM2 represses ΔNp63 expression, whilst in hyperproliferative footpad skin and in TOC 160 
keratinocytes, iRHOM2 positively regulates ΔNp63 expression. 161 
iRHOM2-ADAM17 axis regulates p63 expression 162 
iRHOM2 regulates the maturation of the multi-substrate ectodomain sheddase enzyme 163 
ADAM17 7,8 and, in TOC derived keratinocytes, there is increased cleavage of ADAM17 164 
substrates such as TNFα, IL-6R and EGFR ligands compared to control cells (9). TOC derived 165 
keratinocytes exhibit features of a constitutive “wound-healing” phenotype in which the 166 
iRHOM2-ADAM17 axis plays a key role in skin barrier maintenance, inflammation and 167 
migration 5,9. Here, the modulation of the iRHOM2-ADAM17 axis on p63 expression was 168 
investigated. Western blot analysis (Fig. 3a) revealed that ADAM17 depletion by siRNA led 169 
to an increase of ΔNp63 in control keratinocytes, whilst ΔNp63 was downregulated in TOC 170 
keratinocytes. These data were consistent with our data above in iRHOM2 knock-down cells 171 
(Supplementary Fig. 2f). In agreement, inhibition of ADAM17 using the small molecule TMI-172 
005 increased ΔNp63 in control keratinocytes but decreased its expression in TOC 173 
keratinocytes (Fig. 3b). As TOC derived keratinocytes display an inflammatory phenotype 8,9, 174 
we next assessed whether the secretion of growth factors and cytokines in these cells may 175 
regulate the expression of ΔNp63. 176 
 177 
Surprisingly, we found that conditioned media from TOC derived keratinocytes reduced 178 
ΔNp63 expression (Fig. 3c) in control cells. As TNFα is known to induce keratinocyte 179 
differentiation and modulate p63 expression 23, keratinocytes treated with PMA (phorbol 180 
12-myristate 13-acetate) showed downregulation of ΔNp63 expression in control cells 181 
(Supplementary Fig. 3a) confirming previous studies 24,25. However, the addition of 182 
conditioned media from TOC keratinocytes to TOC keratinocytes with shRNA mediated 183 
knockdown of iRHOM2 showed a restoration of ΔNp63 expression (Fig. 3d). These data 184 
suggested that “the environment” of cell surface shed cytokines and growth factors can 185 
regulate ΔNp63 expression in a cell context dependent manner.  186 
 187 
To examine this putative p63-iRHOM2-ADAM17 axis further, western blot analysis of both 188 
control and TOC keratinocytes with p63 siRNA knockdown (Fig. 3e) revealed reduced 189 
expression of both iRHOM2 and ADAM17. As TOC keratinocytes are characterised by 190 
increased ADAM17 maturation and shedding of its substrates 9, we assessed the role of p63 191 
in the regulation of ADAM17 protease activity. We demonstrated that depletion of p63 in 192 
both control and TOC keratinocytes resulted in decreased ADAM17 maturation and 193 
consequently, a reduction in the “shedding” of TGFα, TNFα and IL-6R (Fig. 3f). To investigate 194 
the mechanism by which p63 regulates ADAM17 expression and its downstream pathway, 195 
we analyzed the available p63 ChIP-seq dataset performed in human and mouse 196 
keratinocytes19,20. This revealed that the human and mouse p63 binding sites are very well 197 
conserved at the intragenic region (Fig. 3g and Supplementary Fig. 3b). Furthermore, ChIP-198 
qPCR confirmed that p63 binds to the ADAM17 gene locus (Fig. 3h). These data indicate that 199 
ADAM17 is a direct p63 target gene. To further investigate whether p63 binding to ADAM17 200 
intragenic region affects ADAM17 expression, p63 isoforms were transiently transfected in 201 
HEK293 cells. In addition, qRT-PCR and western blot analysis showed that overexpression of 202 
TAp63α and ΔNp63α significantly induce ADAM17 at both mRNA and protein level 203 
(Supplementary Fig. 3c and 3d).  Similarly, ADAM17 is also known to be a p73 target gene, 204 
another p53 homologue 26,  such as p63. Thus, these results revealed that p63 can directly 205 
regulate both iRHOM2 and ADAM17 expression. 206 
Additionally, in our previous study 12, we have shown that downregulation of iRHOM2 in 207 
both control and TOC keratinocytes was associated with reduced cell proliferation and 208 
migration. Here we found that depletion of p63 also reduced both proliferation and 209 
migration in control and TOC cell lines (Supplementary Fig. 3e and 3f). 210 
 211 
iRHOM2-p63 axis modulates resistance to apoptosis  212 
TOC epidermis displays improved barrier function, hyperproliferation and thickening of the 213 
palmoplantar 9,12. As exposure to ultraviolet B (UV-B) light is an environmental stressor for 214 
basal keratinocytes, we investigated the cellular response in TOC keratinocytes. Upon UV-B 215 
treatment, TOC keratinocytes showed greater resistance to cell death compared to control 216 
keratinocytes as assessed by annexin-V staining using flow cytometry (Fig. 4a). Furthermore, 217 
control and TOC keratinocytes depleted for iRHOM2 exhibited an induction of apoptosis 218 
(Supplementary Fig. 4a). Depletion of iRHOM2 in TOC keratinocytes increased sensitivity to 219 
UV-B induced apoptosis (Fig. 4b). Moreover, both cell lines depleted for p63 demonstrated 220 
induction of apoptosis following UV-B treatment (Supplementary Fig. 4b). These data 221 
suggest that iRHOM2 and p63 are involved in the regulation of the keratinocyte apoptotic 222 
pathway. Understanding the mechanism(s) through which TOC keratinocytes displayed 223 
resistance to cell death, the expression of inhibitors of apoptosis proteins (IAP) was 224 
investigated. Western blot analysis revealed an increased expression of SURVIVINin TOC 225 
keratinocytes compared to control cells whilst expression of the other members of the IAP 226 
family were unchanged (Supplementary Fig. 4c). We also investigated the effect of UV-B 227 
stimulation on iRHOM2, ΔNp63 and SURVIVNexpression by western blot analysis. We first 228 
confirmed that the cells undergo apoptosis by assessing the expression of PARP, and 229 
observed lower levels of PARP cleavage in TOC keratinocytes after UV-B exposure in 230 
comparison to control cells. iRHOM2, ΔNp63 and SURVIVIN expression was virtually absent 231 
in UV-B exposed control keratinocytes but only slightly lower in TOC keratinocytes (Fig. 4c). 232 
 233 
To explore this putative regulation of SURVIVINby iRHOM2 further, confocal analysis 234 
revealed an increase in SURVIVINexpression in the cytoplasm and the nuclei of basal layer of 235 
keratinocytes in TOC epidermis, compared to control interfollicular skin (Fig. 4d). 236 
Immunostaining in rhbdf2-/- mouse skin showed increased levels of SURVIVINexpression in 237 
the back skin but reduced levels in their footpads in comparison to rhbdf2+/+ littermate 238 
controls (Fig. 4e). In addition, we also confirmed the modulation of SURVIVINexpression by 239 
western blot analysis of protein extracts taken from back skin and paw of rhbdf2+/+ and 240 
rhbdf2-/- mice (Supplementary Fig. 4d). 241 
In agreement with data obtained from rhbdf2-/- mice, depletion of iRHOM2 resulted in an 242 
increase of SURVIVINprotein expression in control keratinocytes and a reduction in TOC 243 
keratinocytes (Supplementary Fig. 4e). To further explore the molecular mechanism by 244 
which iRHOM2 regulatesSURVIVIN, we investigated whether the two proteins are associated 245 
in a complex. Co-immunoprecipitation analysis showed that endogenous iRHOM2 was able 246 
to efficiently immunoprecipitate SURVIVINin control keratinocytes (Fig. 4f) and that 247 
endogenous SURVIVINforms a complex with iRHOM2 (Supplementary Fig. 4f). Taken 248 
together our data demonstrated that iRHOM2 is involved in the regulation ofSURVIVIN.  249 
 250 
As the depletion of p63 and iRHOM2 in both control and TOC keratinocytes induced 251 
apoptosis, we explored a possible regulation of SURVIVINby p63. Prior studies have shown 252 
that SURVIVINis negatively regulated by wild -type p53 but not mutated p53 27. To identify 253 
transcriptional regulators of BIRC5, we analysed the available p63 ChIP-seq dataset 254 
performed in human and mouse keratinocytes19,20. This revealed that the human and mouse 255 
p63 binding sites are very well conserved at the intergenic region. (Fig. 4g and 256 
Supplementary Fig. 4g). ChIP-qPCR revealed that p63 binds to BIRC5 gene locus (Fig. 4h). 257 
These data indicate that BIRC5 is a direct p63 target gene. To further investigate whether 258 
p63 binding to BIRC5 intergenic region affects SURVIVINexpression, p63 isoforms were 259 
transiently transfected in HEK293 cells. Results showed by qRT-PCR analysis that cells 260 
overexpressing TAp63α and ΔNp63α induce significantly BIRC5 at mRNA level 261 
(Supplementary Fig. 4h). Western blotting analysis confirmed the same results 262 
(Supplementary Fig. 4i). In addition, depletion of p63 by siRNA reduced endogenous 263 
expression of SURVIVINin both control and TOC keratinocytes (Supplementary Fig. 4j). These 264 
findings support a model of reciprocal regulation between iRHOM2 and ΔNp63 in 265 
hyperproliferative keratinocytes that may play a role in the resistance to apoptosis via 266 
modulation of SURVIVIN. 267 
 iRHOM2-p63 axis regulates oxidative stress 268 
Previous studies have shown that oxidative stress contributes to a form of palmoplantar 269 
keratoderma (pachyonychia congenita) 28, as well as inflammation 29, and may suppress 270 
apoptosis and promote proliferation 30. Therefore, we investigated whether the iRHOM2 271 
pathway could play a role in ROS (reactive oxygen species) regulation. We examined the 272 
production of ROS in the cells using DHE (Dihydroethidium) dye by flow cytometry. In this 273 
assay ROS convert non-fluorescent DHE to fluorescent ethidium, which then intercalates 274 
into DNA. We found that TOC keratinocytes showed increased level of ROS compared to 275 
control cells (Fig. 5a). However, a reduction in DHE stained cells was observed in both 276 
control and TOC keratinocytes depleted for iRHOM2 (Fig. 5b). We also showed a significant 277 
decrease of ROS level in control and TOC keratinocytes depleted for iRHOM2 by flow 278 
cytometry (Supplementary Fig. 5a). Similarly, we also assessed the role of p63 in the 279 
regulation of ROS. An increase of ROS production in control keratinocytes depleted for p63 280 
was observed while the levels were downregulated in TOC cells silenced for p63 281 
(Supplementary Fig. 5b).  282 
 283 
In order to explore a potential mechanism through which the p63-iRHOM2 axis may control 284 
oxidative stress in TOC keratinocytes, we evaluated the expression of genes associated with 285 
antioxidant pathways such as NQO1 (NAD-(P)H:quinone oxidoreductases), HMOX1 (Heme 286 
Oxygenase 1), SOD1 (Superoxide Dismutase 1) and CYGB Cytoglobin) by qRT-PCR. We 287 
observed a down regulation of these antioxidant genes in TOC keratinocytes compared to 288 
control (Fig. 5c) which are correlated with the increase levels of ROS in TOC keratinocytes. 289 
Interestingly, dysregulation of NRF2 was reported to contribute to palmoplantar 290 
keratoderma 28 . We investigate whether NRF2 may play a role in our pathway. Our data 291 
showed that NRF2 is not modulated at mRNA levels in control and TOC keratinocytes 292 
(Supplementary Fig. 5c) as well in the cells depleted for iRHOM2 (Supplementary Fig. 5d). 293 
Our studies then focussed on CYGB as it is a known p63 target gene 31 and ROS scavenger 32-294 
34 plus CYGB is also transcriptionally down-regulated in TOC oesophagus 35,36. Confocal 295 
analysis showed reduced CYGBexpression in the basal layer of TOC epidermis compared to 296 
control interfollicular skin (Supplementary Fig. 5e). We also confirmed that p63 depletion 297 
led to a reduction of CYGB in control cells by qRT-PCR. However, in TOC cells, p63 siRNA 298 
resulted in an upregulation of CYGB expression (Supplementary Fig. 5f). These findings 299 
observed in TOC cells with p63 siRNA are correlated with the modulation of ROS observed in 300 
those cells. 301 
 302 
To further support a role for iRHOM2 in CYGBregulation, an increase in Cygb expression was 303 
observed by confocal analysis in both back skin and footpad from rhbdf2-/- mice compared 304 
to rhbdf2+/+ (Fig. 5d). In addition, we also confirmed modulation of CYGB expression by 305 
western blot analysis of  protein extracts derived from the back skin and paw of rhbdf2+/+ 306 
and rhbdf2-/- mice (Fig. 5e). Similarly, shRNA knock-down of iRHOM2 showed an 307 
upregulation of CYGBin both control and TOC keratinocytes by western blot analysis (Fig. 308 
5f). These data are correlated with the observed reduction of ROS production in iRHOM2-309 
depleted cells and suggest a possible interaction may be occurring between iRHOM2 310 
andCYGB. To investigate this possible interaction, Proximity-ligation assay (PLA) was 311 
performed in control keratinocytes and showed intense signals corresponding to formation 312 
of complexes between iRHOM2 and CYGB(Fig. 5g). Also, co-immunoprecipitation analysis 313 
showed that endogenous CYGBwas able to efficiently immunoprecipitate iRHOM2 in control 314 
keratinocytes (Supplementary Fig.5g). These data indicate that iRHOM2 interacts with and 315 
repressesCYGB, plus suggest both p63 and iRHOM2 participate in regulating the oxidative 316 
stress response. 317 
 318 
SFN suppresses p63- iRHOM2 pathway in TOC 319 
Oxidative stress has been linked previously to palmoplantar keratoderma associated with 320 
Keratin 16 (K16) mutations, and the use of SFN (Sulforaphane), a natural isothiocyanate 321 
compound found in cruciferous vegetables, rescued the palmoplantar keratoderma 322 
phenotype in K16-/- mice 28. Furthermore our recent study 12 has shown that rhbdf2-/- mice 323 
footpad showed a thinner epidermis, demonstrating that iRHOM2 regulates 324 
hyperproliferation and thickening of the palmoplantar epidermis. To explore whether SFN 325 
could affect TOC keratinocytes, cells were treated with this compound and analysed for ROS 326 
production by flow cytometry. Data showed that SFN treatment significantly reduced ROS 327 
production in TOC keratinocytes (Fig. 6a). Moreover, the treated TOC cells showed a 328 
significant reduction in cell proliferation (Fig. 6b) and were undergoing apoptosis (Fig. 6c). 329 
To investigate if SFN could regulate p63-iRHOM2 and associated downstream pathways, 330 
western blot analysis was performed and showed a downregulation of iRHOM2, ΔNp63 and 331 
SURVIVINbut an upregulation of CYGBfollowing SFN treatment (Fig. 6d). In agreement with 332 
our previous report demonstrating that iRHOM2 regulates the stress-response keratin, K16 333 
12, a downregulation of K16 expression (Fig. 6d) and the collapse of K16 filaments network 334 
upon SFN treatment in TOC keratinocytes was observed (Fig. 6e). It has been reported that 335 
apoptosis can result in keratin solubilisation, filament organization and collapse 37. In 336 
support of the positive feedback loop occurring between ΔNp63 and iRHOM2 in 337 
hyperproliferative keratinocytes, TOC keratinocytes silenced for p63 also demonstrated a 338 
downregulation of K16 (Supplementary Fig. 5h). Together, these data support the 339 
hypothesis that SFN inhibits the p63-iRHOM2 signalling pathway. SFN treatment reduced 340 
TOC-cell proliferation similarly to p63 (Supplementary Fig. 3e) or iRHOM2 12 341 
downregulation. These cells also showed a reduction of ADAM17 mediated shedding of 342 
TGFα and IL-6R (Fig. 6f). Importantly, SFN treatment restored CYGBexpression and reduced 343 
ROS levels. Moreover, SFN-treated cells also displayed a reduced SURVIVINexpression and 344 
were more sensitive to cell death. The increase in apoptosis was confirmed with the 345 
activation of p53 by phosphorylation of serine 15 (Fig. 6d).These findings indicated that SFN 346 
reduces the activation of p63-iRHOM2 pathway in TOC keratinocytes, resulting in reduced 347 




Gain-of-function mutations in RHBDF2, the gene encoding iRHOM2, underlie Tylosis with 352 
Oesophageal Cancer (TOC)5, a syndrome characterized by palmoplantar thickening. We have 353 
recently shown the role of iRHOM2 in determining footpad thickness in humans and mice 12, 354 
with rhbdf2-/- mice displaying a thinner footpad epidermis, the opposite of the phenotype 355 
observed in human TOC palmoplantar epidermis. These data support an important role for 356 
iRHOM2 in regulating the epithelial response to stress. In this present study we provide new 357 
insights into the functional role of iRHOM2 in skin epidermal homeostasis. Here, iRHOM2 358 
has been identified as a new transcriptional target of p63 that is regulated in a cell context 359 
dependent manner. Considering that iRHOM2 is a key regulator of EGFR signalling and that 360 
iRHOM2 mutations cause an increase in the maturation and activity of ADAM17, we 361 
investigated its downstream pathway. Our data revealed that p63 has an impact on 362 
ADAM17 and its associated substrates demonstrating a role of p63 in inflammatory skin 363 
diseases. In addition, we are also reporting that iRHOM2-ADAM17 axis regulates p63 364 
expression. These findings highlight a novel regulation linking iRHOM2 and p63 and suggest 365 
that some common pathways are occurring in keratinocyte homeostasis. We have recently 366 
validated a model of study 12 in which we have established that mouse footpad skin and 367 
human TOC keratinocytes are considered to be a hyperproliferative model, compared to 368 
murine back skin and normal keratinocytes, which are equivalent to physiological 369 
conditions.  370 
 371 
In the normal physiological state, such as in control keratinocytes or in mouse back skin, p63 372 
positively regulates iRHOM2 while it antagonises ΔNp63 expression (Fig. 7). Thus, in this 373 
context, p63 depletion leads to a down regulation of its novel or known target genes such as 374 
iRHOM2, ADAM17, SURVIVIN and CYGB31. In contrast, iRHOM2 downregulation “de-375 
represses” p63 which in turn activates its downstream target genes such as 376 
SURVIVINandCYGB. Our findings emphasise a critical role for the p63-iRHOM2 axis in normal 377 
skin. These data support previous findings showing significant roles for both p63 26,27,31 and 378 
iRHOM2 12 in regulating cellular proliferation, migration and inflammation. 379 
 380 
In the hyperproliferative state, TOC keratinocytes depleted for iRHOM2 and rhbdf2-/- 381 
footpad skin showed a downregulation of ΔNp63 expression. Our data highlight the fact that 382 
inflammation in TOC keratinocytes supports a hyperproliferative phenotype with ΔNp63 383 
overexpression. These findings indicate that iRHOM2 positively regulates ΔNp63 expression 384 
in TOC. Consequently, we observed an increased expression of p63 target genes in 385 
hyperproliferative keratinocytes. Moreover, p63 depletion reduces iRHOM2 expression in 386 
TOC keratinocytes. Thus, this indicates that there is an auto-regulatory feedback loop 387 
occurring between iRHOM2 and ΔNp63 in the hyperproliferative state (Fig. 7), with similar 388 
regulation in proliferation, migration and inflammation.  389 
  390 
Towards understanding the mechanisms through which TOC keratinocytes responded to 391 
stressors, we investigated how these cells respond to UVB treatment. This study allow us to 392 
identify survivin as a p63 target gene, which contributes to apoptosis resistance 38, 393 
confirming previous reports attributing a role of ΔNp63 in cell survival 39,40. In addition, we 394 
have shown a key role for iRHOM2 in apoptosis via its direct regulation of SURVIVIN. Thus, 395 
in TOC keratinocytes, p63 siRNA or shRNA knock-down of iRHOM2 induces apoptosis and 396 
shows SURVIVINdown regulation. These observations confirmed previous studies 397 
demonstrating that SURVIVINis often upregulated in cancer and dysplasia driving resistance 398 
to cell death and contributing to progression of neoplasia 41. 399 
 400 
Hyperproliferation and dysregulation of apoptosis are related to ROS production as it plays a 401 
role in these processes 30. We have identified CYGB, a known p63 target gene 31, as a key 402 
modulator of ROS production in TOC keratinocytes. Prior studies have associated CYGBwith 403 
cancer suppression 42 especially in oesophageal cells 36, and reported a transcriptional 404 
downregulation of CYGB in TOC . We confirmed low levels of CYGBexpression in TOC and 405 
now identify CYGBas a novel interacting binding partner of iRHOM2. Thus, either the 406 
depletion of p63 or iRHOM2 in TOC keratinocytes, as well in rhbdf2-/- footpad skin, increases 407 
CYGBexpression, which in turn dampens ROS release, indicating that the iRHOM2-p63 408 
pathway influences maintenance of the redox status. 409 
 410 
In TOC keratinocytes, the natural antioxidant compound, sulforaphane (SFN) reduced ROS 411 
production and strikingly inhibited the iRHOM2-p63 pathway which can drive survival and 412 
inflammation. Previous studies have reported that SFN possesses potent chemopreventive 413 
efficacy in cancers 43 by inducing apoptosis 44, NRF2 mediated induction of phase II 414 
detoxifying enzymes 45, protecting multiple organs from oxidative injuries 46 and reducing 415 
the inflammatory response 47. Additionally, it has been well established that these different 416 
mechanisms act synergistically 48. Consistent with a recent study, oxidative stress and 417 
dysfunctional NRF2 underlies the palmoplantar keratoderma disorder pachyonychia 418 
congenita with SFN treatment reducing the aberrant keratinisation in K16 -/- mice 28. Our 419 
findings demonstrate that SFN could also be used pharmacologically in TOC keratinocytes to 420 
target the downstream effects of the iRHOM2-p63 pathway, especially through 421 
CYGBinduction. Thus, it is noteworthy to observe that SFN seems to mimic the depletion of 422 
p63 or iRHOM2 in TOC keratinocytes. As we have shown previously that rhbdf2-/- mice 423 
footpad showed a thinner epidermis 12 with absence of K16 expression, SFN treatment may 424 
have a similar impact on the hyperproliferative skin and oesophageal phenotype in TOC 28. 425 
This study supports the model of the iRHOM2-p63 pathway regulating inflammation, 426 
hyperproliferation, oxidative stress and cell survival. Thus targeting of the iRHOM2-p63 axis 427 
in keratinisation disorders and dysplasia could have therapeutic potential. 428 
 429 
Figure Legends 430 
Figure 1: Identification of iRHOM2 as a p63 target gene in keratinocytes.  431 
(a) Screenshot of the UCSC genome browser from ChIP-seq analysis of normal human 432 
primary keratinocytes with two different antibodies (4A4, pan-p63 and H129, α-specific). 433 
The ChIP-seq study was previously reported. (b) Chromatin immunoprecipitation in control 434 
keratinocytes (CTRL) with anti-pan p63 (H137) and anti-IgG antibodies followed by 435 
quantitative PCR (ChIP-qPCR) analysis showed that p63 binds to RHBDF2 intragenic region. 436 
Error bars represent SEM of three independent experiments and Student’s two-tailed t-test 437 
value is shown; p < 0.001 (***). (c) Luciferase assay for RHBDF2 gene locus. The construct 438 
was transiently transfected into HEK293 cells in the absence (-) or in the presence of 439 
ΔNp63α or TAp63α. The (+) control corresponds to IRF6p229-Luc plasmid. The activity of the 440 
intragenic region was measured by luciferase assay and values are expressed relative to (-) 441 
set to 1.  Data were analysed using two-tailed Student’s t-test (p < 0.05 (*), p < 0.01 (**) and 442 
p < 0.001 (***)). (d) qRT-PCR for RHBDF2 in HEK293 cells transfected with TA and ΔNp63 443 
isoforms. The graph represents means and SEM of three biological replicates after 9 hours 444 
of transfection. Statistical analysis was performed by Student’s two-tailed t-test comparing 445 
pcDNA transfected cells to other samples. (e) Immunoblotting of HEK293 cells over-446 
expressing p63 isoforms, showed TA and ΔNp63 isoforms (α-pan p63) and iRHOM2 447 
expression after 9 hours of transfection. GAPDH was used as loading control. The graph 448 
represents the means of the quantification, using ImageJ software, from three independent 449 
experiments relative to GAPDH. Error bars represent SEM and Student’s two-tailed t-test 450 
values are given p < 0.05 (*). (f) Representative Western blotting (WB) shows expression of 451 
ΔNp63 and iRHOM2 in normal keratinocytes (CTRL) treated with non-targeted protein (NTP) 452 
or p63 siRNAs. GAPDH was used as a loading control.  453 
 454 
Figure 2. Distinct regulation of p63 in normal and hyperproliferative keratinocytes.  455 
(a) Representative images of H&E stained sections, displaying a hyperproliferative epidermis 456 
in TOC compared to normal interfollicular skin. Confocal microscopy analysis shows p63 (α-457 
pan p63) expression in TOC and in control interfollicular skin. DAPI (blue) is used as a nuclear 458 
stain. Scale bars: 20 µm. Graph represents quantifications of p63 expression in ratio with the 459 
nuclei from three human samples. Student’s two-tailed t-test value is shown, p < 0.01 (**). 460 
(b) Representative H&E stained back skin and fore-paw sections from 20-week-old rhbdf2+/+ 461 
and rhbdf2-/- mice. Scale bar: 20 μm. Confocal analysis of p63 (α-pan p63) expression was 462 
performed in back skin and fore-paw sections of rhbdf2+/+ and rhbdf2-/- mice. Scale bar: 20 463 
µm. (c) qRT-PCR for ΔNp63 from mRNA extracted from back skin and fore-paws of rhbdf2+/+ 464 
and rhbdf2-/- mice. The graph shows n=6 of each genotype. The statistical analysis was 465 
performed using Student’s two-tailed t-test (p < 0.05 (*), p < 0.01 (**)).  466 
 467 
Figure 3. iRHOM2-ADAM17 axis regulates p63 expression.  468 
(a) Expression of ADAM17 and ΔNp63 by WB in control (CTRL) and TOC keratinocytes 469 
transfected with non-targeting pool (NTP) and ADAM17 siRNA. (b) Immunoblotting of 470 
ΔNp63 expression performed in CTRL and TOC keratinocytes treated with and without TMI-471 
005 for 24 h. (c) Immunoblotting for ΔNp63 in CTRL keratinocytes and  (d) in Sh Scr 472 
(Scramble) and Sh iRHOM2 TOC keratinocytes treated with or without conditioned media 473 
(CM) for 24 h. GAPDH was used as a loading control. (e) WB analysis for ΔNp63, iRHOM2 474 
and ADAM17 in normal and TOC keratinocytes with NTP and p63 siRNA. TUBULIN was used 475 
as a loading control. All the quantifications included were performed by ImageJ software in 476 
comparison to the loading control in three independent experiments. Student’s t test was 477 
used, (p<0.05 (*) and p<0.01 (**)). (f) Levels of TNF-α, TGF-α and IL-6R were assessed by 478 
ELISA from the supernatant of NTP, p63 and ADAM17 siRNAs in CTRL and TOC keratinocytes. 479 
Data are expressed as mean with SEM from four experiments. Statistical analysis was 480 
compared to NTP siRNA CTRL or TOC using one way ANOVA Dunnett’s multiple comparison 481 
test (p<0.05 (*), p<0.01 (**) and p<0.001(***)). (g) Screenshot of the UCSC genome browser 482 
from ChIP-seq analysis of normal human primary keratinocytes with two different 483 
antibodies (4A4, pan-p63 and H129, α-specific). The ChIP-seq study was previously reported. 484 
(h) Chromatin immunoprecipitation in control keratinocytes (CTRL) with anti-pan p63 (H137) 485 
and anti-IgG antibodies followed by quantitative PCR (ChIP-qPCR) analysis showed that p63 486 
binds to ADAM17 intragenic region. Error bars represent SEM of three independent 487 
experiments. For statistical evaluation Student’s two tailed t-test was used (p < 0.01 (**)). 488 
 489 
Figure 4. iRHOM2-p63 axis regulates apoptosis in keratinocytes by modulating SURVIVIN.   490 
(a) Percentage of apoptotic cells was quantified by using flow cytometric analysis of 491 
annexin-V-positive populations in control (CTRL) and TOC keratinocytes after 24 h of UV-B 492 
irradiation (10 or 25 mJ cm-2). Data represent means and SEM of four experiments. 493 
Statistical analysis was performed comparing TOC keratinocytes treated with 10 or 25 494 
mJ/cm2 and CTRL cells treated at the same doses using Student’s two-tailed t-test (p < 495 
0.05(*)). (b) Percentage of apoptotic cells was quantified by using flow cytometric analysis 496 
of annexin-V-positive populations in Sh Scr and Sh iRHOM2-transfected TOC keratinocytes 497 
irradiated with 10 or 25 mJ/cm2 for 24 h. Data represent mean with SEM of five 498 
independent experiments. For statistical evaluation Student’s two tailed t-test was used 499 
(p<0.05 (*), p < 0.01 (**)). (c) Immunoblotting for PARP, cleaved PARP (PARPc), ΔNp63, 500 
iRHOM2 and SURVIVIN in UVB irradiated CTRL and TOC keratinocytes with 10 or 25 mJ cm-2 501 
UV-B treatment. GAPDH is used as a loading control. (d) Representative confocal microscopy 502 
images from immunostaining of SURVIVIN in normal and TOC skin. DAPI (blue) is used as a 503 
nuclear stain. Scale bar: 20 µm. (e) Immunostaining of SURVIVIN was performed in back skin 504 
and fore-paw sections of rhbdf2+/+ and rhbdf2-/- mice by confocal microscopy. DAPI (blue) is 505 
used as a nuclear stain. Scale bar: 20 µm. (f) CTRL keratinocyte lysates were 506 
immunoprecipitated using an anti-iRHOM2 antibody and immunoblotted with anti-507 
SURVIVIN antibody. (g) Screenshot of the UCSC genome browser from ChIP-seq analysis of 508 
normal human primary keratinocytes with two different antibodies (4A4, pan-p63 and H129, 509 
α-specific). The ChIP-seq study was previously reported. (h) Chromatin immunoprecipitation 510 
in control keratinocytes (CTRL) with anti-pan p63 (H137) and anti-IgG antibodies followed by 511 
ChIP-qPCR analysis showed that p63 binds to the BIRC5 intergenic region. Error bars 512 
represent SEM of three independent experiments. For statistical evaluation Student’s two 513 
tailed t-test was used (p < 0.01 (**)). 514 
 515 
Figure 5. iRHOM2 regulates oxidative stress in hyperproliferative keratinocytes.  516 
(a) Quantification of Dihydroethidium (DHE) staining in control (CTRL) and TOC 517 
keratinocytes by flow cytometry. Data are expressed as mean and SEM of three 518 
independent experiments. Statistical analysis was performed to compare CTRL and TOC cells 519 
using Student’s two-tailed t-test (p < 0.01(**)). (b) DHE staining (red) in live Sh Scr or Sh 520 
iRHOM2-transfected CTRL and TOC keratinocytes by confocal microscopy. Hoechst 33342 521 
(blue) was used to identify nuclei. (c) qRT-PCR of HMOX1, NQO1, SOD and CYGB in TOC 522 
keratinocytes was assessed as fold change compared to CTRL cell expression (dashed line). 523 
The graph represents means and SEM of three biological replicates. Statistical analysis was 524 
performed comparing CTRL and TOC keratinocytes using Student’s two-tailed t-test (p < 525 
0.05(*), p < 0.01(**), p < 0.001(***)). (d) Immunostaining of CYGB was performed in fore-526 
paw and back skin sections of rhbdf2+/+ and rhbdf2-/- mice by confocal microscopy. DAPI 527 
(blue) is used as nuclear stain. Scale bar: 20 µm. (e) Representative WB for CYGB expression 528 
from proteins extracted from back skin and fore-paw of rhbdf2+/+ and rhbdf2-/- mice. GAPDH 529 
was used as a loading control. (f) WB analysis of CYGB in Sh Scr and Sh iRHOM2-transfected 530 
CTRL and TOC keratinocytes. GAPDH was used as a loading control. (g) Representative 531 
confocal images from PLA experiments between iRHOM2 and CYGB in control keratinocytes. 532 
PLA between K6 and K16 was performed as a positive (+) control, while no primary 533 
antibodies were applied in negative (-) control. 534 
  535 
 536 
Figure 6. SFN represses iRHOM2-p63 pathway in TOC  537 
(a) Quantification of DHE staining by flow cytometry in TOC keratinocytes treated with 538 
dimethyl sulfoxide (DMSO; the vehicle control), and sulforaphane (SFN) (10 µM) for 24 h. (b) 539 
Growth curves of TOC cells cultured with SFN (10 µM) or DMSO for 0, 24 and 48 hrs post 540 
treatment. Data are expressed as mean ± SEM. (c) Percentage of apoptotic cells was 541 
quantified by using flow cytometry analysis of annexin-V- positive populations detected 542 
after 24 h incubation with SFN (10 µM) or DMSO, in TOC cells. Bars represent mean values 543 
with SEM of four experiments. (d) Immunoblotting of lysates from TOC keratinocytes 544 
treated with SFN (10 µM) or DMSO for 24 h and analysed for ΔNp63, iRHOM2, SURVIVIN, 545 
K16, p53, phopho-p53 and CYGB expression. GAPDH is used as a loading control. (e) 546 
Immunofluorescence staining of K16 in TOC cells after 0, 6 and 24 hours of SFN incubation. 547 
Scale bar: 20 µm. (f) ELISA for TGF-α and IL-6R with the supernatants of TOC cells treated 548 
with SFN (10 µM) or DMSO for 24 h. All data are expressed as mean and SEM of three 549 
experiments. Statistical analysis was performed by Student’s two-tailed t-test (p<0.05 (*) 550 
and p<0.01 (**)). 551 
 552 
Figure 7. Proposed model. 553 
Model illustrating the regulation of iRHOM2-p63 pathway under normal and 554 
hyperproliferative states. 555 
Materials and Methods 556 
Cell Culture and reagents 557 
TOC cells are immortalized keratinocytes from a Tylosis patient carrying the UK RHBDF2 558 
mutation have been describedpreviously 5.. Control keratinocytes carrying the same 559 
immortalization with human papilloma virus (HPV-16) open reading frames E6 and E7 as TOC 560 
cells. Cells were cultured in DMEM (Sigma), supplemented with 10% foetal bovine serum 561 
(FBS), 1% penicillin–streptomycin (pen-strep), 100uM L-Glutamine (Sigma) and keratinocyte 562 
growth supplement RM+ (RM+: containing EGF).  HaCaT and HEK293 cells were cultured in 563 
DMEM supplemented with 10% FBS, 1% pen-strep and 100uM L-Glutamine. All cells were 564 
cultured in sterilized conditions at 37°C with 5% of CO2. RHBDF2 or negative scrambled shRNA 565 
for control and TOC keratinocytes were previously described 12. 566 
Antibodies  567 
The list of the used antibodies are reported in Supplementary Information (Supplementary 568 
Table 1) .  569 
Treatments 570 
For treatment (UV-B, Phorbol 12-myristate 13-acetate (PMA), condition media (CM), 571 
TMI005, Ca2+ and Sulforaphane (SFN)), cultured cells were plated at the density of 2x105 572 
cells in 6-well plates and allowed to attach overnight at 37˚C, after 24 h, cells were treated. 573 
For UV-B, cells were irradiated at 10 and 25 mJ/cm2. After UVB irradiation, the media was 574 
aspired and fresh culture medium was added (samples untreated were just changed with 575 
fresh medium). The cells were then harvested at 24 h post irradiation. For PMA (Sigma) 576 
treatment, the media was supplemented by the addition of 250 ng/ml PMA for 24 h. In 577 
condition media experiments, media from TOC keratinocytes, was centrifuged to eliminate 578 
any cells, then filtered using 0.2 µm filter (Millipore) and diluted in complete media (1:2). 579 
After these procedures the media was added to the cells for 24 h. For TMI005 (Apratastat, 580 
1507 Axon Medchem UK) was dissolved in dimethyl sulfoxide (DMSO) and stock solution 581 
was freshly prepared and added to the cells at the final concentration of 500 nM for 24 h. 582 
The same DMSO concentration used to dilute the TMI005 was utilised as a negative control. 583 
To induce differentiation, calcium (2mM) was added in the medium with 2% of FBS, when 584 
the cells until reaching approximately 90% confluence to induced differentiation. SFN was 585 
purchased from Sigma and was dissolved in dimethyl sulfoxide (DMSO) at the concentration 586 
of 40 mg/ml for the stock solution. SFN was added to cell cultures to obtain the final 587 
concentration of 10 µM, samples were analysed after 24 and 48 hours post treatment.  588 
ChIP assay 589 
. Chromatin was prepared from normal keratinocytes and immunoprecipitated with 590 
antipan-p63 (H137) overnight at 4°C. ChIP assays were performed as previously described21. 591 
DNA extraction was carried out with phenol–chloroform. Purified DNA was diluted in water 592 
and subjected to qRT-PCR. Primer sequences used: ADAM17 F: 5’- 593 
CCTCACAATACTCAGCAAAA -3’, ADAM17 R: 5’- AGTCAGTAGGAGTGATTATG-3’; RHBDF2 F: 5’- 594 
TGTGCCCTTGCTTACCCCTG -3’, RHBDF2 R: 5’- CACTCATTTGCTCCTCCAGAC-3’; BIRC5 F: 5’- 595 
CTCCTTTCCTGGTGCACCT-3’, BIRC5 R: 5’- CGGGGTGTGGTCCCTTTGGA-3’; TK F: 5’-596 
GTGAACTTCCCGAGGCGCAA-3’, TK R: 5’-GCCCCTTTAAACTTGGTGGGC-3’; p21 F: 5’-597 
ATGTATAGGAGCGAAGGTGCA-3’, p21 R: 5’-CCTCCTTTCTGTGCCTGAAACA-3’; Chr11 F: 5’-598 
TTGCATATAAAGGAAACTGAAATGCT-3’, Chr11 R: 5’-TTACTGCCATGGGTCCGTATC-3’. 599 
Transfection  600 
HEK293 cells were transfected by using Lipofectamine 2000 reagent (Invitrogen) at a 1:2 601 
(ml/mg) ratio with DNA, using 5 mg of plasmid DNA. The plasmids for p63 overexpression 602 
were a generous gift from Dr Eleonora Candi. 603 
Gateway Cloning and Luciferase Reporter Assays 604 
To generate an RHBDF2 promoter reporter vector, recombinant plasmids were constructed 605 
using the Gateway cloning system (Invitrogen). A genomic fragment corresponding to the 606 
promoter region of RHBDF2 was PCR amplified using primers flanked by directional attB 607 
sites, after which this fragment was integrated into the pDONR221 gateway donor vector 608 
(Invitrogen) using BP clonase (Invitrogen). The following, attB-flanked, primers were used 609 
for the amplification of the RHBDF2 promoter region – 610 
Forward:GGGGACAAGTTTGTACAAAAAAGCAGGCTACCTGGAGGCTCACTCCAC 611 
TCT Reverse: GGGGACCACTTTGTACAAGAAAGCTGGGTTGGGATTACAGGCATGAG. 612 
 After transformation of OneShot TOP10 chemically competent E.coli (Thermo Fisher) and 613 
selection using kanamycin-containing LB medium, this vector was purified and analysed by 614 
restriction digestion using NaeI and HpaI restriction endonucleases. Entry clones with 615 
correct integration were then used to clone the promoter sequence into a modified pGL3-616 
Enhancer vector (modified to contain attR integration sites) using LR clonase (invitrogen). 617 
Once again, these vectors were used to transform OneShot TOP10 competent E.coli, which 618 
were selected using LB medium containing ampicillin, purified, and analysed for correct 619 
integration by restriction digestion using EcoNI and NheI endonucleases. For luciferase 620 
reporter assays, HEK293 cells were plated at a density of 5x104 cells per well into 96-well 621 
plates. 24 hours later, 50ng of transient expression vectors encoding either TAp63α or 622 
ΔNp63α were transfected into these HEK293 cells either alone or alongside 50ng of the 623 
firefly luciferase-expressing pGL3-RHBDF2 vector or the positive control IRF6_BS2_p229 624 
vector, in addition to 5ng of an internal control Renilla luciferase reporter vector, using 625 
lipofectamine transfection reagent. After 24 more hours, lysates were collected by treating 626 
with 20μl passive lysis buffer per well for 15 minutes. Luciferase was assayed by the Dual-627 
Luciferase system (Promega), with data presented as luciferase activity relative to 628 
untransfected cells. 629 
RNA interference 630 
For p63 knockdown, siRNA sequences against TP63 (ID 217143, ID 4893 and ID 217144 from 631 
Applied Biosystems) were used in combination to create a siRNA-p63 pool. For ADAM17 632 
knockdown, siRNA sequences specific to against ADAM17 (L-003453-00-0005, OnTarget plus 633 
SMARTPool ADAM17 siRNA, Dharmacon Lafayette, USA,). As a negative control, a non-634 
targeting siRNA pool (D-001810-10-20, ON-TARGETplus, Dharmacon Lafayette, USA) was 635 
selected. Transfection was performed according to the manufacturer’s protocol and 636 
optimized for a six-well plate. Normal and TOC keratinocytes were plated at 50% confluency 637 
and subjected to transfection on the following day using the transfection reagent Dharma 638 
FECT 1 (Thermo Fisher Dharmacon) and 60 nM final concentration of each siRNA. During 639 
siRNA application, antibiotics were removed from the cell culture medium.  Transfection 640 
media were replaced with complete DMEM after 24 h. p63 and ADAM17 expression were 641 
assessed by western blot after 48 h.  642 
Immunoblot and co-immunoprecipitation 643 
After performing specific treatments, cells were harvested, washed three times with 644 
phosphate-buffered saline (PBS) and then lysed using lysis buffer [1 M Tris, 2.5 M NaCl, 10% 645 
glycerol, 0.5 M glycerophosphate, 1% Tween-20, 0.5% Nonidet P-40 and  EDTA-free 646 
Complete Protease Inhibitor tablet (Roche)] for 15 min on ice. Protein concentration was 647 
measured using a Bradford Assay Kit (Bio-Rad). Equal amounts of protein were loaded and 648 
separated by sodium dodecyl sulphate–polyacrylamide gel electrophoresis, SDS-PAGE (on 649 
10% or 12% polyacrylamide gels) and transferred to a nitrocellulose membrane (Whatman). 650 
The blots were incubated with the specific antibodies and developed according to the 651 
manufacturer’s instructions (ECL Immobilion Western, Millipore). Antibodies were diluted in 652 
PBS containing 5% milk and 0.01% Tween 20. Co-immunoprecipitation experiments were 653 
performed as previously described 12. Briefly, the lysates were collected after 30 minutes 654 
and pre-cleared by centrifugation at 13,000 rpm for 10 minutes at 4°C. Protein 655 
concentration was calculated using the Bradford Protein Assay system (Bio-Rad). 50µl of 656 
Sepharose protein G (Amersham) were prepared according to manufacturer’s instructions. 657 
IgG (Rabbit IgG sc-2027,) was used as a control. 2mg of protein lysate was added to beads 658 
and antibodies (2µg) incubated overnight at 4°C with rotation. The following day beads were 659 
washed three times for 5 minutes on ice in 1 ml of NP-40 wash buffer (50mM Tris pH 8.0, 660 
150mM NaCl, 1mM EDTA, 1% NP40) containing protease and phosphatase inhibitors 661 
(Roche). Beads were separated from antibody-protein complexes by boiling for 5 minutes in 662 
2x Laemelli buffer and loaded onto a gel for SDS-PAGE electrophoresis. Uncut blots are 663 
supplied in Supplementary Figure 6. 664 
qRT-PCR 665 
Total RNA was prepared with RNeasy mini Kit (Qiagen). cDNA was synthesized using High-666 
Capacity cDNA Reverse Transcription Kits strand (Thermo Scientific) for RT-PCR according to 667 
the manufacturer's instructions. Semi-quantitative PCR was carried out using Maxima SYBR 668 
Green/ROX qPCR master mix (Thermo Scientific, UK). Measurements were done in triplicate 669 
and normalized to levels of GAPDH mRNA for each reaction and analysed using the equation 670 
n = 2-ΔΔCt. The following primers were used for qPCR analysis: for human genes GAPDH 671 
forward 5’-GGAGTCAACGGATTTGGTC-3’ and reverse 5’-GGCAACAATATCCACTTTACC-3’; 672 
ΔNp63 forward 5’-GAGTTCTGTTATCTTCTTAG-3’ and reverse 5’- TGTTCTGCGCGTGGTCTG-3’;; 673 
HMOX1 forward 5’-AAAGTGCAAGATTCTGCCC-3’ and reverse 5’- GAGTGTAAGGACCCATCGG-674 
3’; NQO1 forward 5’- TCTATGCCATGAACTTCAATCC-3’ and reverse 5’- 675 
CTTCAGTTTACCTGTGATGTC-3’; SOD1 forward 5’- GGATGAAGAGAGGCATGTTGGAGAC-3’ and 676 
reverse 5’- GTCTTTGTACTTTCTTCATTTCCACC-3’; CYGB forward 5’- CTGTCGTGGA 677 
GAACCTGCAT-3’ and 5’- TGGAGTTAGGGGTCCTACGG-3’; RHBDF2 forward 5’- 678 
GGGCAAACTCAGACTCGAAG-3’ and reverse 5’- CGCTGACTCCAAACCACTG-3’, ADAM17 679 
forward 5’- GGTTCCTTTCGTGCTGGCGC-3’ and reverse 5’- AAGCTTCTCGAGTCTCTGGTGGG-3’; 680 
NRF2 forward 5’- CAGCGACGGAAAGAGTATGA-3’ and reverse 5’-TGGGCAACCTGGGAGTAG-681 
3’. For mouse genes ΔNp63 forward 5’- GTACCTGGAAAACAATGCCCAG-3’ and reverse 5’-682 
CGCTATTCTGTGCCTGGTCTG-3’; GAPDH forward 5’- ACCACAGTCCATGCCATCAC-3’ and 683 
reverse 5’- TCCACCACCCTGTTGCTGTA-3’. 684 
The enzyme-linked immunosorbent assay (ELISA) 685 
After performing specific treatments, cell culture supernatants were used to detect TNF-α, 686 
IL-6R and TGF-α by ELISA using the human DuoSet ELISA kit as to the manufacturer’s 687 
instructions (R&D System, UK). Results were expressed as means of four independent 688 
experiments with triplicate samples. 689 
Immunofluorescence 690 
Immunohistochemistry was performed on 5 mm frozen tissue or on cells plated in cover 691 
slips; sections were air-dried before processed. Cells/tissues were fixed in 4% 692 
paraformaldehyde (PFA) or in ice cold Methanol-Acetone (50:50 mixture) at room 693 
temperature for 15 min. If PFA fixation was used, samples were permeabilized with 0.1% 694 
Triton X-100. Cells/tissues were washed three times with PBS for 5 min each and incubated 695 
with 5% goat serum in PBS for 1 hour at room temperature to reduce nonspecific binding.  696 
After the cells/tissue were incubated with primary antibody in 5% goat serum overnight at 697 
4˚C. The following day cells/tissues were washed three times with PBS and incubated with 698 
the secondary antibody conjugated with Alexa Fluor (Molecular Probes) in 5% goat serum 699 
for 1 h at room temperature. After three washes, cells/sections were incubated for 10 min 700 
with DAPI (100 ng/ml). Cells/tissues were mounted onto slides using Vectashield Mounting 701 
Medium (Vector Laboratories). Fluorescence was evaluated in one single plane by Zeiss 710 702 
confocal microscopy (Carl Zeiss). 703 
Haematoxylin and Eosin (H&E) 704 
Tissue sections were fixed in 4% PFA and stained with haematoxylin and eosin. 705 
 706 
Cell proliferation 707 
To analyse cell proliferation after performing transfection with siRNA, cells were plated at a 708 
seeding density of 1x104 per well and then harvested at 24 and 48 h. For SFN exposure, cells 709 
were seeded at 1x104 per well and then treated with SFN at 10 µM. Cells were counted after 710 
24 and 48 hours post treatment. Cell counts were performed using the 711 
Nucleocounter/Nucleocasette system (ChemoMetec, Denmark). Each experiment was 712 
repeated three times with triplicate samples. 713 
Scratch assay 714 
Cells were seeded into six-well plates in culture medium and were transfected with siRNA. 715 
The cells were incubated with mitomycin C (400 ng ml-1, Roche) for 45 min to prevent 716 
proliferation. The scratch wound was created vertically to the centre of the well using a 717 
sterile tip to 200 µl. The cells were subsequently washed with PBS to remove the detached 718 
cells and then replenished with fresh medium. The woundwas monitored and 719 
photographed immediately (time 0) and after 24 h from the creation of the scratch using a 720 
phase-contrast microscope. The wound area was evaluated by using Image J Software. The 721 
percentage was calculated using the following equation: [Wound Area (0h) - Wound Area 722 
(Xh)] x 100 /Wound Area (0h) = % Wound Closure. 723 
Annexin V assay 724 
Apoptosis was assessed by flow cytometry using FITC Annexin-V (Becton Dickinson) and 725 
DAPI. The cells were harvested by the addition of trypsin, centrifuged for 5 min at 1200 rpm, 726 
and washed with PBS. Cells were stained with FITC-Annexin V for 15 minutes and the DAPI 727 
(200 ng/ml) was added. Samples were analysed by a BD FACSCanto ІІ Flow Cytometer (BD, 728 
UK). Data were expressed as means of total apoptosis, the sum of early and late apoptosis. 729 
The gating strategy is reported in Supplementary Fig.7. 730 
Proximity ligation assay (PLA) 731 
PLA was performed using the Duolink in situ kit (Sigma) according to the manufacturer’s 732 
instructions. Cells were plated on coverslips in twelve-well plates and after 24 h fixed with 733 
Methanol Acetone or PFA. Following fixation, cells were incubated in Duolink blocking 734 
solution for 30 min at 37°C. Primary antibodies were diluted in Duolink Antibody diluent and 735 
added to the cells overnight at 4°C. The following day the cells were washed in Wash buffer 736 
A two times for 5 min. The PLA plus and minus probes were diluted in antibody diluent and 737 
added to the cells, then incubated for 1 h at 37°C. The cells were washed in Wash buffer A 738 
two times for 5 min. The Ligation–Ligase was prepared according to instructions and applied 739 
to cells for 30 min at 37°C. After washes, amplification with Duolink Amplification-740 
Polymerase solution was performed for 100 min at 37°C. The cells were washed in Wash 741 
Buffer B two times for 10 min and then mounted with Duolink in situ mounting medium 742 
with DAPI before visualization with Zeiss 710 confocal microscopy (Carl Zeiss). As a positive 743 
control binding between K6 and K16 was analysed, while as a negative control no primary 744 
antibodies were applied. Quantifications were performed using Image J Software. 745 
Measurement of ROS Production 746 
The quantification of intracellular ROS was based on the oxidation of dihydroethidium (DHE, 747 
Thermo Fisher). Briefly, normal and TOC keratinocytes (2x105) were plated in each well of 6-748 
well plate. Cells were then washed twice with PBS and incubated with DHE (5µM) at 37°C 749 
for 30 min in the dark. After incubation, the cell were washed twice with PBS and were 750 
analysed by a BD FACSCanto ІІ Flow Cytometer (BD, UK). Data represented the value of ROS 751 
in the live cells by a ratio referred to the control. For staining, normal and TOC keratinocytes 752 
(5x104) were plated on cover slip in each well of 12-well plate. The cells on cover slip were 753 
washed twice with HBSS after exposure to DHE (Thermo Scientific) working concentration 754 
(5µM) at 37 °C for 30 min in the dark. Before microscopy, Hoechst® 33342 (0.1 μg/ml, 755 
Thermo Scientific) was added to stain the nuclei. The fluorescence was analysed using Zeiss 756 
710 confocal microscopy (Carl Zeiss). 757 
Mouse studies 758 
rhbdf2-/- mice were generated as previously described 12. The fore paw footpad epidermis 759 
from twenty-week-old rhbdf2-/- or WT female mice were dissected and fixed in OCT on dry 760 
ice. Immunohistochemical staining was performed as previously described and visualized 761 
using the Zeiss 710 Confocal Microscope (Carl Zeiss). Biopsies from WT female mice (n=6 per 762 
genotype, back and paw skin) were snap frozen, pulverized, and dissolved in TRIzol reagent 763 
for RNA preparation (Invitrogen) according to manufacturer’s protocol. RNA samples were 764 
treated with RNase-free DNaseI (Qiagen). Western blot analysis of mouse skin extract were 765 
prepared in urea buffer 8M (8M urea, 1M thiourea, 0.5% CHAPS, 50 mM DTT, 24 mM 766 
spermine). 767 
Study approval 768 
All experiments involving mice followed the UK Animal Welfare Act guidelines and were 769 
approved by the UK Home Office (PPL 70/7665). Human skin biopsies were approved by the 770 
research ethics committees of the National Health Service (08/H1102/73) and informed 771 
consent was obtained from participants. 772 
Statistical analysis 773 
All statistical analyses were performed with Prism 6 Software (GraphPad). Data were 774 
analysed by the unpaired/paired two-tailed Student’s t test and one way ANOVA Dunnett’s 775 
multiple comparison test. All experiments were performed at least three times 776 
independently or more indicated in the legends. The data are expressed as the mean ± 777 
standard error of mean (SEM).  778 
[p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***)] 779 
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